Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573859 | 0.87 | CCR5 (0.44) | CCR5KMT2ARIPK1NSD3 | |
| SCHEMBL4597902 | 0.87 | CCR5 (0.44) | CCR5KMT2ARIPK1NSD3 | |
| SCHEMBL4598546 | 0.85 | ALDH1A1 (0.41) | CCR5HTR3AALDH1A1MDM2TP53 | |
| SCHEMBL5572460 | 0.81 | STS (0.47) | CCR5MEN1KMT2ANPSR1TP53 | |
| SCHEMBL4610211 | 0.80 | CCR5 (0.37) | CCR5 | |
| SCHEMBL5573722 | 0.74 | CCR5 (0.38) | CCR5RIPK1NSD3 | |
| SCHEMBL5573716 | 0.74 | CCR5 (0.38) | CCR5RIPK1NSD3 | |
| SCHEMBL4552558 | 0.72 | CCR5 (0.47) | CCR5 | |
| SCHEMBL14571163 | 0.70 | RIPK1 (0.43) | CCR5KMT2ASRD5A1RIPK1NSD3 | |
| SCHEMBL14571188 | 0.70 | ALDH1A1 (0.40) | CCR5HTR3AALDH1A1MDM2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | CCR5 1/4885MEN1 4855/4885KMT2A 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.